Artiva Biotherapeutics exchanges underwater options for RSUs for CEO and COO

Artiva Biotherapeutics, Inc.

CEO Fred Aslan surrendered 869,136 options (566,470 vested, 302,666 unvested) for equivalent RSUs with new vesting.
COO Jennifer Bush surrendered 84,877 options (60,372 vested, 24,506 unvested) for equivalent RSUs.
RSUs vest between Aug 2026 and Feb 2029; acceleration on termination without cause or resignation for good reason.
Purpose: retain employees and align interests with stockholders by replacing underwater options with current-value equity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.